![]() ![]() The data are significant and some patients who received pembrolizumab remain in treatment-free remissions, Raez concludes. In the first-line setting, the open-label, randomized, phase III KEYNOTE-024 trial, showed that pembrolizumab was more effective if compared with platinum-based chemotherapy in NSCLC patients with high levels of PD-L1 expression tumor proportion score (TPS) of 50 or higher ().Brahmer et al. However, the utility of pembrolizumab in patients with metastatic NSCLC is dependent on PD-L1 expression, Raez explains. This is important because less than 5% of this patient population could be cured only 20 years ago, but the 5-year survival data from KEYNOTE-024 showthe number has drastically increased. Now, 5-year survival have emerged, demonstrating clinically meaningful long-term overall survival benefit with the checkpoint inhibitor compared with chemotherapy, Raez says. 8,19,20 Taken together, these data provide support for an association between PD-L1 TPS assessed. The KEYNOTE-024 trial evaluated pembrolizumab (Keytruda) vs platinum-based chemotherapy regimens in patients with metastatic NSCLC. However, efficacy outcomes in this study and the observed association between tumor PD-L1 expression and OS are consistent with data from randomized controlled trials with more limited follow-up, including KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042. PD-L1 expression were randomized to receive either. The median OS in the pembrolizumab group was at least. ![]() KEYNOTE-204 (NCT02684292) was a randomized, international, open-label, phase III study of pembro vs BV in R/R cHL. Raez, MD, FACP, FCCP, hematology and oncology, Medical Director, Chief Scientific Officer, Memorial Cancer Institute, Memorial Healthcare System, discusses the clinical implications of the phase 3 KEYNOTE-024 trial (NCT02142738) in non–small cell lung cancer (NSCLC). KEYNOTE-02411 was a phase 3 trial in which 305 pa- tients who had untreated, advanced NSCLC with high. The data from KEYNOTE024 indicated that pembrolizumab monotherapy could provide meaningful improved patient outcomes over platinumbased chemotherapy for advanced NSCLC patients with PDL1 TPS 50 but without sensitizing EGFR or ALK mutations in the firstline treatment setting. 8005 Background: PD-1 blockade via pembro monotherapy showed antitumor activity in R/R cHL.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |